XW033E5
XW033E5 — Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
Billable / specific codeICD-10-PCS
CMS abbreviated title: Introduce Remdesivir in Periph Vein, Perc, New Tech 5
How XW033E5 is built
Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.
- XSectionNew Technology — What family of procedure this is
- WBody systemWhich system it acts on
- 0Root operationThe objective — the verb of the procedure
- 3Body partThe specific site
- 3ApproachHow the site was reached
- EDeviceWhat was left in place, if anything
- 5QualifierA further distinction where one applies
Codes near XW033E5
In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.
- XW0339AIntroduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW033A7Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
- XW033B7Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033BAIntroduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW033C7Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033CAIntroduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW033DAIntroduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW033E5Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
- XW033F3Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
- XW033F5Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
- XW033FAIntroduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW033FBIntroduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11
- XW033G5Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
- XW033G6Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
- XW033G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033H5Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5